The EFS benefit was greater in patients with higher stage NSCLC than in those with lower stage NSCLC (HR 0.54 for stage IIIA vs. 0.87 for stage IB and II), patients with PD-L1 expression ≥ 50% (HR 0.24) than in patients with tumor PD-L1 of 1% to 49% (HR 0.58) or PD-L1 lower than 1% (HR 0.85), and in patients with non-squamous NSCLC than squamous one (HR 05 vs. HR 0.77, respectively). This evidence concerns the gene CD274 and neoplasm.